What is the equity of SenzaGen this year?
SenzaGen has equity of 67.61 M SEK this year.
SenzaGen Equity 2024
SenzaGen Equity
67.61 M SEK
Ticker
SENZA.ST
ISIN
SE0010219626
WKN
A2DX79
In 2024, SenzaGen's equity was 67.61 M SEK, a -24.63% increase from the 89.7 M SEK equity in the previous year.
SenzaGen Aktienanalyse
What does SenzaGen do?
SenzaGen AB is a Swedish biotechnology company that specializes in the development and marketing of innovative and reliable tests for assessing allergenicity. Founded in 2010 by leading experts from the academic and industry sectors, the company has become a significant player in the field of toxicology. Current methods for assessing allergenicity, such as asthma, eczema, and allergic reactions, are often inaccurate and require the use of animals, which is ethically questionable and expensive. SenzaGen AB has developed a wide range of tests based on biomolecular technologies that use human cells to assess the allergenic reactivity of chemicals and products. These tests are accurate, cost-effective, and meet the current requirements of regulatory authorities and the industry. The company is headquartered in Lund, Sweden, and currently employs about 20 people. SenzaGen AB is a leader in the development of in vitro methods for evaluating allergenicity and utilizes various platform technologies such as gene expression and proteomics analysis, as well as the use of immune cells and keratinocytes. SenzaGen AB's Microarray technology platform, based on DNA-based tests, has been recognized by the European Chemicals Agency (ECHA) as suitable for assessing allergenic reactivity. The company has also partnered with the US biotechnology company In vitro International (IVI) to distribute its allergen tests in the North American market. SenzaGen AB has developed a wide range of products that can be used in various sectors such as cosmetics, food, chemicals, and pharmaceuticals. AllergoDx™ is a test system used by the pharmaceutical and chemical industries to determine the allergenic reactivity of chemicals. GARD™ (Genomic Allergen Rapid Detection) is a rapid test used in the cosmetics and food industries to determine the allergenic reactivity of new products and avoid costly animal testing. GARDskin™ is a skin test used to determine the reactivity of substances that come into contact with the skin, primarily in the chemicals and pharmaceutical industries. Other products in the company's pipeline include GARDpotency™ and GARDair™, which are intended for assessing allergic reactions in industrial and occupational environments. SenzaGen AB has experienced significant growth in recent years and plans to expand its product range and strengthen its market position. The company's business model is based on selling tests and services to chemical, pharmaceutical, food, and cosmetic companies worldwide. Through its innovative technologies and willingness to collaborate with customers, the company has taken a leadership role in toxicology. SenzaGen AB is committed to an ethical and responsible corporate philosophy focused on sustainability and environmental protection. The company has clear goals to meet the growing demand for reliable and ethical testing methods to minimize the impact of chemicals on humans and the environment. SenzaGen ist eines der beliebtesten Unternehmen auf Eulerpool.com.Equity Details
Analyzing SenzaGen's Equity
SenzaGen's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding SenzaGen's equity is essential for assessing its financial health, stability, and value to shareholders.
Year-to-Year Comparison
Evaluating SenzaGen's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.
Impact on Investments
SenzaGen's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.
Interpreting Equity Fluctuations
Fluctuations in SenzaGen’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.
Frequently Asked Questions about SenzaGen stock
What was the equity of SenzaGen compared to the previous year?
The equity of SenzaGen has increased/decreased by -24.63% decreased compared to the previous year.
What impact does a high equity have on investors of SenzaGen?
A high equity is advantageous for investors of SenzaGen as it is an indicator of the company's financial stability and its ability to manage risks and challenges.
What impact does low equity have on investors of SenzaGen?
A low equity can be a risk for investors of SenzaGen, as it can put the company in a weaker financial position and impair its ability to manage risks and challenges.
How does an increase in equity of SenzaGen affect the company?
An increase in equity of SenzaGen can strengthen the company's financial position and improve its ability to make investments in the future.
How does a reduction in the equity of SenzaGen affect the company?
A reduction in equity of SenzaGen can affect the financial situation of the company and lead to a higher dependence on debt capital.
What are some factors that influence the equity of SenzaGen?
Some factors that can affect the equity of SenzaGen include profits, dividend payments, capital increases, and acquisitions.
Why is the equity of SenzaGen so important for investors?
The equity of SenzaGen is important for investors as it is an indicator of the financial strength of the company and can be an indication of how well the company is able to fulfill its financial obligations.
What strategic measures can SenzaGen take to change the equity?
To change equity, SenzaGen can take various measures such as increasing profits, conducting capital increases, reducing expenses, and acquiring companies. It is important for the company to perform a thorough review of its financial situation to determine the best strategic actions to modify its equity.
How much dividend does SenzaGen pay?
Over the past 12 months, SenzaGen paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, SenzaGen is expected to pay a dividend of 0 SEK.
What is the dividend yield of SenzaGen?
The current dividend yield of SenzaGen is .
When does SenzaGen pay dividends?
SenzaGen pays a quarterly dividend. This is distributed in the months of .
How secure is the dividend of SenzaGen?
SenzaGen paid dividends every year for the past 0 years.
What is the dividend of SenzaGen?
For the upcoming 12 months, dividends amounting to 0 SEK are expected. This corresponds to a dividend yield of 0 %.
In which sector is SenzaGen located?
SenzaGen is assigned to the 'Health' sector.
Wann musste ich die Aktien von SenzaGen kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of SenzaGen from 10/4/2024 amounting to 0 SEK, you needed to have the stock in your portfolio before the ex-date on 10/4/2024.
When did SenzaGen pay the last dividend?
The last dividend was paid out on 10/4/2024.
What was the dividend of SenzaGen in the year 2023?
In the year 2023, SenzaGen distributed 0 SEK as dividends.
In which currency does SenzaGen pay out the dividend?
The dividends of SenzaGen are distributed in SEK.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
Andere Kennzahlen von SenzaGen
Our stock analysis for SenzaGen Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of SenzaGen Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
